WHO R&D Blueprint novel Coronavirus (nCov) Vaccine prioritization for clinical trials
Appropriate WHO Confidentiality Undertakings were signed and submitted to WHO by all participating experts
Overview
The current global nCoV public health emergency underscores the need to accelerate the development of nCoV candidate vaccines. The Working Group for vaccine prioritization aims to provide aspirational guidance to vaccine developers from a public health perspective as well as to prioritize vaccine platform approaches and/or candidates to be considered for further development and potentially consider for latestage evaluation in the context of the global nCoV outbreak.
Objectives of the consultation
The objectives of this consultation were:
- To review the current pipeline of candidate vaccines for nCoV
- To review the current pipeline of candidate vaccines for other coronaviruses and discuss their value in protecting against the nCoV.
- To make preliminary recommendations on whether the development of nCoV candidate vaccines should be prioritized over the development of other coronaviruses candidate vaccines.
This Consultation presents an initial step towards the evaluation of candidate vaccines against this novel Coronavirus. There are ongoing efforts to identify additional candidate vaccines and to expand the body of evidence available on each of the candidates.